跳至主要内容
临床试验/NL-OMON43969
NL-OMON43969已完成不适用

The supplementary role of cardiovascular magnetic resonance imaging and computed tomography angiography to routine clinical practice in suspected non-ST elevation myocardial infarction. A randomized controlled trial. - Non-invasive imaging in suspected NSTEMI CARMENTA trial

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 207 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
207

研究概览

简要总结

Trial ended prematurely

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • *Prolonged symptoms suspected of cardiac origin (angina pectoris or angina
  • equivalent), and presentation on the cardiac ED <24 hours after symptom onset
  • *Increased highly sensitive troponin-T level (hs-TnT *0.014*g/L) (initial blood sample at presentation or a second sample *3 hours after presentation)
  • *Age 18 years * 85 years
  • *Willing and capable to give written informed consent
  • *Written informed consent

排除标准

  • *Ongoing severe ischemia requiring immediate ICA (at discretion of cardiac ED
  • physician/cardiologist)
  • *Shock (mean arterial pressure < 60 mmHg) or severe heart failure (Killip Class * III)
  • *STEMI (ST-elevation in 2 contiguous leads: *0.2mV in men or *0.15 mV in women in leads V2-V3
  • and/or *0.1 mV in other leads or new left bundle branch block)
  • *Chest pain highly suggestive of non-cardiac origin (as judged by the cardiac ED
  • physician/cardiologist):
  • o Acute aortic dissection
  • o Acute pulmonary embolism (high risk patient defined as Wells score >6)
  • o Musculoskeletal or gastro-intestinal pain
  • o Other (pneumothorax, pneumonia, rib fracture, etc.)
  • *Previously known coronary artery disease (CAD), defined as:
  • o Any non-invasive diagnostic imaging test positive for CAD (perfusion defects, and/or stress induced wall motion abnormalities)
  • o Coronary stenosis >50% on any previous ICA or CTA
  • o Documented previous myocardial infarction
  • o Documented previous coronary artery revascularization (PCI and/or CABG)
  • *Known cardiomyopathy (dilated, hypertrophic, infiltrative, etc.)
  • *Pregnancy
  • *Life threatening arrhythmia on the cardiac ED or prior to presentation
  • (sustained ventricular tachycardia, repetitive non-sustained ventricular tachycardia, ventricular
  • fibrillation, sino-artial or atrio-ventricular block)
  • *Atrial fibrillation
  • *Tachycardia (*100/bpm) induced angina pectoris
  • *Angina pectoris secondary to anemia (<5.6 mmol/L), untreated hyperthyroidism, aortic valve stenosis (AVA * 1.5 cm2), or severe hypertension (>200/110 mmHg)
  • *Life expectancy <1 year (malignancy, etc.);*Contraindications to CMR:
  • ODIN protocol: *Uitvoering van MRI onderzoek bij patiënten met een cardiaal implanteerbaar elektronisch device (CIED), waaronder een pacemaker en ICD*
  • ODIN protocol: *Voorbereiding klinische patiënten voor MRI onderzoek*
  • o Metallic implant (vascular clip, neuro-stimulator, cochlear implant)
  • o Pacemaker or implantable cardiac defibrillator (ICD)
  • o Claustrophobia
  • o Body weight >130 kg;*Contraindication to CMR or CTA contrast agent (Gadolinium or Iodine):
  • ODIN protocol: *Voorbereiding bij contrastonderzoeken of -interventies met intravasculair gebruik van jodiumhoudende contrastmiddelen; voorkomen van contrastnefropathie, CIN, hydratieschema*
  • o Renal failure (estimated GFR *30 mL/min/1,73m2) / chronic renal failure stage 4-5 (details for
  • CTA arm in appendix D: detailed CTA protocol)
  • o Known severe contrast allergy (patient with mild allergy is eligible for inclusion
  • when pre-medication according to hospital guidelines can be administered);*Contraindication to adenosine:
  • o High degree atrio-ventricular block (2nd or 3rd degree)
  • o Severe asthma bronchiale
  • o Chronic obstructive pulmonary disease Gold * III
  • o Concomitant use of dipyridamole (Persantin)
  • o Long QT syndrome (congenital)

研究者

发起方
Medisch Universitair Ziekenhuis Maastricht

相似试验